ACT 335827Orexin receptor 1 antagonist,potent and selective CAS# 1354039-86-3 |
- Cevimeline
Catalog No.:BCC1470
CAS No.:107233-08-9
- Tolterodine tartrate
Catalog No.:BCC4586
CAS No.:124937-52-6
- Darifenacin HBr
Catalog No.:BCC4567
CAS No.:133099-07-7
- Solifenacin succinate
Catalog No.:BCC4580
CAS No.:242478-38-2
- Fesoterodine Fumarate
Catalog No.:BCC4584
CAS No.:286930-03-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1354039-86-3 | SDF | Download SDF |
PubChem ID | 54765113 | Appearance | Powder |
Formula | C31H38N2O5 | M.Wt | 518.64 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO and to 100 mM in ethanol | ||
Chemical Name | (2R)-2-[(1S)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-2-phenyl-N-propan-2-ylacetamide | ||
SMILES | CC(C)NC(=O)C(C1=CC=CC=C1)N2CCC3=CC(=C(C=C3C2CC4=CC(=C(C=C4)OC)OC)OC)OC | ||
Standard InChIKey | HXHOBPVRRPCTLG-SETSBSEESA-N | ||
Standard InChI | InChI=1S/C31H38N2O5/c1-20(2)32-31(34)30(22-10-8-7-9-11-22)33-15-14-23-18-28(37-5)29(38-6)19-24(23)25(33)16-21-12-13-26(35-3)27(17-21)36-4/h7-13,17-20,25,30H,14-16H2,1-6H3,(H,32,34)/t25-,30+/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent and selective orexin OX1 receptor antagonist (Kb values are 41 and 560 nM for OX1 and OX2 receptors respectively). Elicits anxiolytic effects in vivo. Brain penetrant and orally available. |
ACT 335827 Dilution Calculator
ACT 335827 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.9281 mL | 9.6406 mL | 19.2812 mL | 38.5624 mL | 48.203 mL |
5 mM | 0.3856 mL | 1.9281 mL | 3.8562 mL | 7.7125 mL | 9.6406 mL |
10 mM | 0.1928 mL | 0.9641 mL | 1.9281 mL | 3.8562 mL | 4.8203 mL |
50 mM | 0.0386 mL | 0.1928 mL | 0.3856 mL | 0.7712 mL | 0.9641 mL |
100 mM | 0.0193 mL | 0.0964 mL | 0.1928 mL | 0.3856 mL | 0.482 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
ACT 335827 is a potent and selective antagonist of OXR-1 with IC50 values of 120 and 2300 nM for OXR-1 and OXR-2, respectively [1].
Orexin receptor 1 (OXR-1) is a G-protein coupled receptor for neuropeptide orexin-A and regulates feeding behaviour. OXR-1 is expressed in the hypothalamus.
ACT 335827 is a potent and selective OXR-1 antagonist with Kb values of 41 and 560 nM for OXR-1 and OXR-2, respectively [1].
In the fear-potentiated startle rats, ACT-335827 (300 mg/kg) inhibited fear-induced startle reactions. Also, ACT-335827 (300 mg/kg) significantly reduced stress-induced tachycardia and hyperthermia. In the rat polydipsia model, ACT-335827 (300 mg/kg) inhibited compulsive drinking behavior [1]. In rats exposed to novelty stress, ACT-335827 (100 mg/kg) reduced the tachycardic and pressor by 48% and 32%, respectively [2]. In a diet-induced obesity(DIO) rat model, ACT-335827 increased the level of high-density lipoprotein and water intake. Also, it slightly increased body weight, which suggested that inhibition of OXR-1 had minimal impact in this model [3].
References:
[1]. Steiner MA, Gatfield J, Brisbare-Roch C, et al. Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist. ChemMedChem, 2013, 8(6): 898-903.
[2]. Beig MI, Dampney BW, Carrive P. Both Ox1r and Ox2r orexin receptors contribute to the cardiovascular and locomotor components of the novelty stress response in the rat. Neuropharmacology, 2015, 89: 146-156.
[3]. Steiner MA, Sciarretta C, Pasquali A, et al. The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome. Front Pharmacol, 2013, 4: 165.
- KH CB19
Catalog No.:BCC6135
CAS No.:1354037-26-5
- Bullatine A
Catalog No.:BCN2374
CAS No.:1354-84-3
- CX-6258 hydrochloride hydrate
Catalog No.:BCC1505
CAS No.:1353858-99-7
- 8-Prenyldaidzein
Catalog No.:BCN4711
CAS No.:135384-00-8
- 12alpha-Methoxygrandiflorenic acid
Catalog No.:BCN7771
CAS No.:135383-94-7
- 4'-Hydroxyisojasminin
Catalog No.:BCN7383
CAS No.:135378-09-5
- Isojasminin
Catalog No.:BCN7492
CAS No.:135378-08-4
- 5,7,3',4'-Tetrahydroxy-3-methoxy-8,5'-diprenylflavone
Catalog No.:BCN6848
CAS No.:1353676-65-9
- 8,8'-Bibaicalein
Catalog No.:BCN6549
CAS No.:135309-02-3
- MEN 10376
Catalog No.:BCC7133
CAS No.:135306-85-3
- 2''-O-Rhamnosylicariside II
Catalog No.:BCN3464
CAS No.:135293-13-9
- EW-7197
Catalog No.:BCC6467
CAS No.:1352608-82-2
- trans-Ned 19
Catalog No.:BCC7825
CAS No.:1354235-96-3
- JW 480
Catalog No.:BCC6142
CAS No.:1354359-53-7
- 7-O-Prenylscopoletin
Catalog No.:BCN3547
CAS No.:13544-37-1
- Rehmapicrogenin
Catalog No.:BCN8507
CAS No.:135447-39-1
- Strontium Ranelate
Catalog No.:BCC3858
CAS No.:135459-87-9
- Araliadiol
Catalog No.:BCC8835
CAS No.:1354638-93-9
- Cabazitaxel intermediate
Catalog No.:BCN7432
CAS No.:1354900-65-4
- CYM 50260
Catalog No.:BCC6259
CAS No.:1355026-60-6
- ML 190
Catalog No.:BCC6308
CAS No.:1355244-02-8
- 2,3-Dihydro-12,13-dihydroxyeuparin
Catalog No.:BCN7189
CAS No.:135531-75-8
- Mutant IDH1-IN-1
Catalog No.:BCC6403
CAS No.:1355326-21-4
- AGI-5198
Catalog No.:BCC2293
CAS No.:1355326-35-0
Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist.[Pubmed:23589487]
ChemMedChem. 2013 Jun;8(6):898-903.
Stress relief: Orexin neuropeptides regulate arousal and stress processing through orexin receptor type 1 (OXR-1) and 2 (OXR-2) signaling. A selective OXR-1 antagonist, represented by a phenylglycine-amide substituted tetrahydropapaverine derivative (ACT-335827), is described that is orally available, penetrates the brain, and decreases fear, compulsive behaviors and autonomic stress reactions in rats.
The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome.[Pubmed:24416020]
Front Pharmacol. 2013 Dec 30;4:165.
The orexin system regulates feeding, nutrient metabolism and energy homeostasis. Acute pharmacological blockade of orexin receptor 1 (OXR-1) in rodents induces satiety and reduces normal and palatable food intake. Genetic OXR-1 deletion in mice improves hyperglycemia under high-fat (HF) diet conditions. Here we investigated the effects of chronic treatment with the novel selective OXR-1 antagonist ACT-335827 in a rat model of diet-induced obesity (DIO) associated with metabolic syndrome (MetS). Rats were fed either standard chow (SC) or a cafeteria (CAF) diet comprised of intermittent human snacks and a constant free choice between a HF/sweet (HF/S) diet and SC for 13 weeks. Thereafter the SC group was treated with vehicle (for 4 weeks) and the CAF group was divided into a vehicle and an ACT-335827 treatment group. Energy and water intake, food preference, and indicators of MetS (abdominal obesity, glucose homeostasis, plasma lipids, and blood pressure) were monitored. Hippocampus-dependent memory, which can be impaired by DIO, was assessed. CAF diet fed rats treated with ACT-335827 consumed less of the HF/S diet and more of the SC, but did not change their snack or total kcal intake compared to vehicle-treated rats. ACT-335827 increased water intake and the high-density lipoprotein associated cholesterol proportion of total circulating cholesterol. ACT-335827 slightly increased body weight gain (4% vs. controls) and feed efficiency in the absence of hyperphagia. These effects were not associated with significant changes in the elevated fasting glucose and triglyceride (TG) plasma levels, glucose intolerance, elevated blood pressure, and adiposity due to CAF diet consumption. Neither CAF diet consumption alone nor ACT-335827 affected memory. In conclusion, the main metabolic characteristics associated with DIO and MetS in rats remained unaffected by chronic ACT-335827 treatment, suggesting that pharmacological OXR-1 blockade has minimal impact in this model.